TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00945490
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intraprostatic injection of placebo
Study: NCT00428597
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match sunitinib taken daily (oral) on the same schedule as active agent below.
Study: NCT03436615
Drug: SB206 4%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily
Study: NCT03436615
Drug: SB206 8%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily
Study: NCT03436615
Drug: SB206 12%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once or twice daily
Study: NCT03436615
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once or twice daily
Study: NCT00817011
Drug: SSRI treated group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant administration of SSRI class for 6 weeks under therapeutic dose
Study: NCT00817011
Drug: non-SSRI treated group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant administration of non-SSRI class for 6 weeks under therapeutic dose
Study: NCT04432558
Drug: Tramadol, paracetamol, diclofenac sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: The analgesic consumption of the patients will be recorded
Study: NCT02107469
Drug: Sida cordifolia roots
Normalized name: Rubia cordifolia root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sida cordifolia roots, crude drug (coarse powder) a plant product 7g (packages prepared) are soaked in 112ml water (measurement cup provided) for 12 hours and then boiled until the level is reduced to 1/4 of hight. Fluid is filtered an drunk after cooling down to room temperature - orally 2 times a day before breakfast and dinner
Study: NCT02107469
Drug: Phyllanthus niruri
Normalized name: PHYLLANTHUS NIRURI WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phyllanthus niruri (whole plant) fine powder 3g three times a day with warm water before meals taken orally.
Study: NCT02107469
Drug: Sida cordifolia roots extract
Normalized name: Rubia cordifolia root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: gelatine capsule with 300mg Sida cordifolia roots spraydry extract 12:1 concentrated normalized to alkaloids (alcoholic/aqueous extract) - 2 capsules taken orally 2 times a day with warm water before meal
Study: NCT02107469
Drug: Phyllanthus niruri extract
Normalized name: Phyllanthus niruri top extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: gelatine capsule with 300mg Phyllanthus niruri spray dry extract 5:1 concentrated normalized to bitters (alcohol/aqueous extract) - 2 capsules taken orally 3 times a day with warm water before meal
Study: NCT03487939
Drug: FOLFOXIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: IRINOTECAN 150 mg/m\^2 IV over 1-h, day 1 + OXALIPLATIN 85 mg/m\^2 IV over 2-h, day 1 + L-LEUCOVORIN 200 mg/m\^2 IV over 2-h, day 1 + 5-FLUOROURACIL 2800 mg/m\^2 IV 48-h continuous infusion, starting on day 1 administered every two weeks for 4 cycles (2 months).
Study: NCT01370863
Drug: SPD557
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg tablet t.i.d. for 4 weeks on top of stable PPI treatment
Study: NCT01370863
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo tablet t.i.d. for 4 weeks on top of stable PPI treatment
Study: NCT00330473
Drug: Human Insulin Inhalation Powder
Normalized name: insulin, regular, human Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: patient specific dose, inhaled, before meals, 9 months ( if patient chooses Human Insulin Inhalation Powder option)
Study: NCT03341169
Drug: N(2)-L-Alanine L-Glutamine dipeptide
Normalized name: N-ethyl-L-glutamine
DrugBank: Theanine (DB12444)
Approvals — FDA: no, EMA: no, PMDA: no
Description: :Intravenous infusion of N (2) -L-alanyl-L-glutamine(mixed with normal saline, ratio 1:1) at the dose of 0.25g/kg(body weight) for 8 hours before induction of anesthesia(rate=2.5\*weight/8 ml/h) and administration another 0.25g/kg(body weight) of N (2) -L-alanyl-L-glutamine(mixed with 8.5% amino acid solution, ratio 1:5) into the central vein for 10 hours after induction of anesthesia(rate=0.75\*weight ml/h)
Study: NCT03341169
Drug: placebo (0.9% NaCl (normal saline))
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 0.9% NaCl for 8 hours before induction of anesthesia(rate=2.5\*weight/8 ml/h) and administration 0.9% NaCl into the central vein for 10 hours after induction of anesthesia(rate=0.75\*weight ml/h)
Study: NCT01441349
Drug: IP chemotherapy plus simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * Cisplatin(30mg/m2)diluted into 150 ml of 0.9% NS for IV over 30 min on day 1 \&8~* Irinotecan( 65 mg/m2) diluted into 200ml of 5DW IV over 90 min on day 1\& 8.~* Every 21days.~* Simvastatin 40 mg per day orally D1of cycle 1
Study: NCT01852799
Drug: PAD Followed by ASCT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Bortezomib, Bortezomib (1.3mg/m2, iv, on day 1, 4, 8, 11, of each 28 day cycle)~Drug: Adriamycin (Doxorubicin) /EPI, Adriamycin (Doxorubicin) (9 mg/m2, iv, on days 1-4 of each 28 day cycle) or EPI (15mg/m2, iv, on days 1-4 of each 28 day cycle)~Drug: Dexamethasone, Dexamethasone (20mg, iv, on days 1-4, 8-11of each 28 day cycle)~After received induction therapy, patients will proceed to receive ASCT based on the willing of the patients and the decision of the investigators.
Study: NCT04610528
Drug: U3 1402
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.4 mg/kg dose
Study: NCT04610528
Drug: U3 1402
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.6 mg/kg dose
Study: NCT01959828
Drug: IK-3001
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02715687
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Will receive 30 days treatment with oral placebo of 200mg
Study: NCT01943565
Drug: spinal anesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine 0.75% 1.6 mL (12mg)
Study: NCT03192397
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01583374
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identically matched placebo tablets were taken orally twice a day during the placebo controlled phase.
Study: NCT01265524
Drug: CLP
Normalized name: Endopeptidase Clp
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT01265524
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT00009945
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 pills PO daily
Study: NCT02994147
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-only control study medication is the same formulation as active treatment without active ingredient
Study: NCT01459380
Drug: Pegylated Liposomal Doxorubicin Hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT02606032
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: active comparator
Study: NCT02606032
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: identical placebos to all antibiotics
Study: NCT00314834
Drug: Intradialytic parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02071914
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo.
Study: NCT01034995
Drug: SSR125543
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: capsule~Route of administration: oral
Study: NCT01034995
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: capsule~Route of administration: oral
Study: NCT05526313
Drug: Prilinostat Mesylate 1.2mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 case,The starting dose,Take the medicine once on D1, D8, D11, D15.
Study: NCT05526313
Drug: Prilinostat Mesylate 2.4mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 case,The starting dose,Take the medicine once on D1, D8, D11, D15.
Study: NCT05526313
Drug: Prilinostat Mesylate 4.0mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 case,The starting dose,Take the medicine once on D1, D8, D11, D15.
Study: NCT05526313
Drug: Prilinostat Mesylate 6.0mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 case,The starting dose,Take the medicine once on D1, D8, D11, D15.
Study: NCT05526313
Drug: Prilinostat Mesylate 8.4mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 case,The starting dose,Take the medicine once on D1, D8, D11, D15.
Study: NCT05526313
Drug: Prilinostat Mesylate 11.2mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 case,The starting dose,Take the medicine once on D1, D8, D11, D15.
Study: NCT05526313
Drug: Prilinostat Mesylate 15mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 case,The starting dose,Take the medicine once on D1, D8, D11, D15.
Study: NCT02227238
Drug: LPV/RTV
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPV/RTV is supplied as the LPV/RTV oral tablet, which contains 200 mg of LPV and 50 mg of RTV
Study: NCT01632306
Drug: LY2090314
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2090314 administered IV
Study: NCT01632306
Drug: FOLFOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX administered IV
Study: NCT01223755
Drug: conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment relates usually to the administration of antihypertensive drugs for patients with high blood pressure. Thus, for the present study, no major change in antihypertensive treatment should be introduced throughout the whole study period unless deemed clinically necessary (the reasons of the changes should be, however, clearly explained in the CRF). Only small changes in the doses of the ongoing treatments are recommended in order to maintain the same level of blood pressure control (target systolic/diastolic blood pressure \<130/80 mmHg). This approach is aimed to minimize the confounding effect of any change in concomitant treatments on some efficacy variables (such as urinary protein excretion rate).
Study: NCT01448200
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules
Study: NCT04154501
Drug: CNTX-6016
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Dose CNTX-6016
Study: NCT02284139
Drug: Arm Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGF Ointment 0ppm evenly apply to skin lesion every 12 hr/ day
Study: NCT00867360
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo medication
Study: NCT01451541
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - one dose per nostril
Study: NCT01225523
Drug: Paclitaxel; Cisplatin; 5-Fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two preoperative cycles with Paclitaxel 200 mg/m² d1, Cisplatin 60 mg/m² d1, 5-Fluorouracil 700 mg/m² d1-5 repeated every 3 weeks followed by resection
Study: NCT01225523
Drug: Paclitaxel; Cisplatin; 5-Fluorouracil; Capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two postoperative cycles with Paclitaxel 200 mg/m²/day d1, Cisplatin 60 mg/m²/day d1, 5-Fluorouracil 700 mg/m²/day d1-5 repeated every 3 weeks Among patients with no responses to preoperative chemotherapy, Capecitabine 625 mg/m² twice-daily dose as alternatives to infused 5-Fluorouracil in the postoperative chemotherapy regimen
Study: NCT00510627
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care chemotherapy regimen
Study: NCT02768974
Drug: OPRX-106
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral delivery, once daily.
Study: NCT01002092
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Week 1 day 1 MTX 8 g/m2; Week 3 day 1-2 CDP 100-120 mg/m2 day 1 ADM/THP 60 mg/m2; Week 5 day 1-6 IFO 2 g/day; Week 7 rest; Week 8 surgery; Two weeks after the surgery repeat the chemotherapy cycle 3 times (6 weeks per cycle).
Study: NCT02736019
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Women will receive oral Celecoxib 200mg 2 hours before the procedure
Study: NCT02736019
Drug: Placebo 1
Normalized name: placebo 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women will receive an oral placebo similar to Tramadol 2 hours before the procedure.
Study: NCT02736019
Drug: Placebo 2
Normalized name: Ethinyl Estradiol/Norethindrone Acetate;Placebo 20 MCG-1 MG; NA Oral Tablet, Disintegrating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women will receive an oral placebo similar to celecoxib 2 hours before the procedure
Study: NCT03324139
Drug: Low molecular weight heparin
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients included in this study group will receive 3,500 IU / 0.2 ml / day of Bemiparina sc, from inclusion to delivery (estimated median of 5-6 weeks, with a maximum of 13 weeks).
Study: NCT03324139
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients included in this study group will placebo (same presentation as the active drug), from inclusion to delivery (estimated median of 5-6 weeks, with a maximum of 13 weeks).
Study: NCT01739647
Drug: AZD3293
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution
Study: NCT01739647
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution
Study: NCT00229944
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01954693
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5mg daily administered for 6 months as two oral 2.5 mg tablets once daily.
Study: NCT04269395
Drug: Vehicle cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intervention will be administered as a part of this study. Participants who received vehicle cream in RD.06.SPR.112199 study and achieved complete response, will be rolled over in the study.
Study: NCT00524056
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: two placebo tablets twice per day
Study: NCT00159432
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00887861
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03815903
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 cycles, each 21 days, of Cisplatin 80mg/m2 plus Paclitaxel 175mg/m2
Study: NCT02542254
Drug: RPL554
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg RPL554 administered using a nebuliser
Study: NCT02542254
Drug: Salbutamol matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pMDI
Study: NCT02542254
Drug: RPL554 matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulised placebo
Study: NCT01139762
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally, once daily for 26 weeks
Study: NCT02313545
Drug: IZN-6NVS Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: IZN-6NVS, a hydrocream containing three herbal extracts, is a polymolecular agent derived from botanical sources. It is composed of a blend of three herbal extracts, Centella asiatica, Echinacea purpurea, and Sambucus nigra.~Cream concentration: 5%
Study: NCT01764633
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.
Study: NCT00388778
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00467571
Drug: lansoprazole, clarithromycin, amoxycillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: lansoprazole (15, 30 mg) 1 tab twice daily, clarithromycin 7.5 mg/kg twice daily, amoxycillin 25 mg/kg twice daily; rout: orally; duration 14 days
Study: NCT00008060
Drug: FOLFIRI regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00008060
Drug: FOLFOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00008060
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00008060
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04219150
Drug: Fluid and Catheter Treatment Trial FACTT Lite
Normalized name: Lite 'N Foamy
Approvals — FDA: no, EMA: no, PMDA: no
Description: The FACTT Lite provided three possible instructions determined by the CVP and urine output: furosemide administration, fluid bolus, or no intervention. FACTT Lite contained instructions to withhold furosemide until the patient achieved a mean arterial pressure greater than 60 mmHg off of vasopressors for at least 12 h.
Study: NCT03273595
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02658214
Drug: cisplatin + 5-fluorouracil (5FU)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT04130464
Drug: Ropivacaine + Ketorolac Infusion from ON-Q Pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of 0.2% ropivacaine + 30 mg ketorolac at 8 mL/hour for 72 hours
Study: NCT04130464
Drug: Normal Saline Infusion from ON-Q Pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of 0.9% normal saline at 8 mL/hour for 72 hours
Study: NCT01472432
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is added to the standard good medical practice. Plus Metformin and/or Sulfonylurea
Study: NCT03098485
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5 days of azithromycin administration
Study: NCT03209115
Drug: combination of calcium hydroxide and chlorhexidine
Normalized name: Calcium Hydroxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: placement of calcium hydroxide and chlorhexidine as intracanal medicament after removal of old filling and mechanical preparation of root canal
Study: NCT03209115
Drug: Calcium Hydroxide
Normalized name: Calcium Hydroxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: placement of calcium hydroxide as intracanal medicament after removal of old filling and mechanical preparation of root canal
Study: NCT03234907
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vedolizumab placebo-matching
Study: NCT02132130
Drug: CGF166
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGF166 is a recombinant adenovirus 5 (Ad5) vector containing the human Atonal transcription factor (Hath1) cDNA for administration via intra-labyrinthine infusion
Study: NCT02483195
Drug: 200mg Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This will be a mixed combination of 5% Minoxidil and 200mg Spironolactone to be used once daily.
Study: NCT04132115
Drug: Gentamicins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic drug monitoring (TDM) of this antibiotic plasma concentration
Study: NCT04132115
Drug: Amikacin
Normalized name: amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Therapeutic drug monitoring (TDM) of this antibiotic plasma concentration
Study: NCT01634685
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: capecitabine, will be delivered twice daily p.o. on the days of radiation treatment, at a dose of 825 mg/m2.
Study: NCT04224584
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will act as a control for duloxetine.
Study: NCT04218487
Drug: Xuefu-Zhuyu Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment with 2.4g (6 capsules) of XFZY three times daily for 12 weeks.
Study: NCT04218487
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment with 2.4g (6 capsules) of placebo three times daily for 12 weeks.
Study: NCT02108639
Drug: DCV 3DAA FDC
Normalized name: DYE FDC BLUE #1
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01951209
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo
Study: NCT04464369
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo pills matching the look and weight of the itopride tablets
Study: NCT01513239
Drug: SOC
Normalized name: Isocet
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOC for CDI will be prescribed for 10 to 14 days and can begin on the day of study drug infusion; but the first dose must have been administered prior to or within a few hours following study drug infusion. SOC is defined as the receipt of oral metronidazole, oral vancomycin, IV metronidazole concurrent with oral vancomycin, oral fidaxomicin, or oral fidaxomicin concurrent with IV metronidazole.
Study: NCT01828294
Drug: Subcutaneous immunoglobulins
Normalized name: immunoglobulin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunoglobulins used subcutaneously for maintenance of other immune mediated disorders.
Study: NCT02346630
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules daily for 3 weeks.
Study: NCT02346630
Drug: Levodopa / Carbidopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa / Carbidopa drug 100/25 mg once a day for 3 weeks.
Study: NCT04508244
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 ampoules of 1 mg placebo solution (3 ampoules/day for 2 days; 2 ampoules/day for day-3 \& 4 and 1 ampoule/day for day-5 \& 6.
Study: NCT00109512
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02152696
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Two Dose Protocol: The patient will receive the first dose of MTX 50mg/m2 on treatment day 0. She will receive a second dose of MTX 50mg/m2 on treatment day 4 and a serum hCG level will be drawn. Subsequent doses of MTX will be administered based on hCG levels.
Study: NCT03891095
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: intranasally administrated and orally administered
Study: NCT00198133
Drug: Premetrexed (Alimta)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed will be 500 mg/m2 IV every 3 weeks
Study: NCT03960801
Drug: Remifentanil group
Approvals — FDA: no, EMA: no, PMDA: no
Description: bolus intravenous injection of 3 to 4µg/kg of remifentanil after hypnotic administration for a crush anesthetic induction